John Heymach
John Heymach
Chair, Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center
Verified email at - Homepage
Cited by
Cited by
Comprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network
Nature 511 (7511), 543, 2014
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
The BATTLE trial: personalizing therapy for lung cancer
ES Kim, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein Jr, A Tsao, ...
Cancer discovery 1 (1), 44-53, 2011
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ...
Science 346 (6206), 256-259, 2014
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor …
LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ...
Clinical cancer research 19 (1), 279-290, 2013
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic …
DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ...
The lancet oncology 17 (12), 1672-1682, 2016
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ...
Nature communications 5 (1), 5241, 2014
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ...
Cancer research 67 (24), 11924-11932, 2007
Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional …
DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ...
Journal of Clinical Oncology 37 (18), 1558, 2019
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCo-occurring …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ...
Nature Reviews Cancer 19 (5), 289-297, 2019
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
JA Engelman, T Mukohara, K Zejnullahu, E Lifshits, AM Borrás, CM Gale, ...
The Journal of clinical investigation 116 (10), 2695-2706, 2006
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ...
Journal of the National Cancer Institute 104 (3), 228-239, 2012
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
RS Herbst, Y Sun, WEE Eberhardt, P Germonpré, N Saijo, C Zhou, ...
The lancet oncology 11 (7), 619-626, 2010
A pan-cancer proteomic perspective on The Cancer Genome Atlas
R Akbani, PKS Ng, HMJ Werner, M Shahmoradgoli, F Zhang, Z Ju, W Liu, ...
Nature communications 5 (1), 3887, 2014
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerDDR Inhibition Enhances Antitumor Immunity in SCLC
T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ...
Cancer discovery 9 (5), 646-661, 2019
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach
Nature Reviews Cancer 19 (9), 495-509, 2019
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
LA Byers, J Wang, MB Nilsson, J Fujimoto, P Saintigny, J Yordy, U Giri, ...
Cancer discovery 2 (9), 798-811, 2012
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer
JW Welsh, R Komaki, A Amini, MF Munsell, W Unger, PK Allen, JY Chang, ...
Journal of Clinical Oncology 31 (7), 895, 2013
The system can't perform the operation now. Try again later.
Articles 1–20